Venetoclax plus bortezomib and dexamethasone in heavily pretreated end‐stage myeloma patients without t(11;14): A real‐world cohort
Sign Up to like & getrecommendations! Published in 2020 at "Hematological Oncology"
DOI: 10.1002/hon.2736
Abstract: Multiple myeloma (MM) is the second most common blood cancer caused by the uncontrolled proliferation of clonal plasma cells. Despite recent advances in treatment, a majority of patients eventually relapse and die because of progressive… read more here.
Keywords: venetoclax; myeloma; bortezomib dexamethasone; bortezomib ... See more keywords
Three cases of relapsed/refractory multiple myeloma under hemodialysis treated with panobinostat/bortezomib/dexamethasone (FVD)
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Hematology"
DOI: 10.1007/s12185-017-2222-4
Abstract: Three patients under hemodialysis (HD) with relapsed/refractory multiple myeloma (MM) were administered panobinostat/bortezomib/dexamethasone (FVD). Case 1: The patient was a 66-year-old male with BJP-κ. FVD was effective, but HD could not be discontinued. He developed… read more here.
Keywords: relapsed refractory; refractory multiple; bortezomib dexamethasone; panobinostat bortezomib ... See more keywords
Activity of panobinostat in combination with bortezomib and dexamethasone in advanced, proteasome inhibitor refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2017 at "memo - Magazine of European Medical Oncology"
DOI: 10.1007/s12254-017-0342-4
Abstract: SummaryThe patient described here presented with relapsed multiple myeloma progressing after therapy with immunomodulatory agents (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib and carfilzomib). Eventually, the patient achieved an excellent response to the combination of… read more here.
Keywords: multiple myeloma; combination; activity panobinostat; bortezomib dexamethasone ... See more keywords
Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of cancer"
DOI: 10.1016/j.ejca.2017.02.004
Abstract: Chemotherapy combining cyclophosphamide, bortezomib and dexamethasone is widely used in light-chain amyloidosis. The benefit is limited in patients with cardiac amyloidosis mainly because of adverse cardiac events. Retrospective analysis of our cohort showed that 39 patients… read more here.
Keywords: bortezomib dexamethasone; cyclophosphamide bortezomib; light; amyloidosis ... See more keywords
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
Sign Up to like & getrecommendations! Published in 2019 at "Blood Cancer Journal"
DOI: 10.1038/s41408-019-0254-0
Abstract: Gain of chromosome 1q (+1q) is commonly identified in multiple myeloma and has been associated with inferior outcomes. However, the prognostic implication of +1q has not been evaluated in the setting of standard triplet regimens.… read more here.
Keywords: gain chromosome; myeloma; bortezomib dexamethasone; multiple myeloma ... See more keywords
Bortezomib and dexamethasone, an original approach for treating multi‐refractory warm autoimmune haemolytic anaemia
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.16009
Abstract: We report the off‐label use of bortezomib combined with dexamethasone in eight adults with severe and multi‐refractory warm auto‐immune haemolytic anaemia (wAIHA). After six cycles of induction therapy, 6 of the 8 patients achieved response… read more here.
Keywords: response; bortezomib dexamethasone; multi refractory; refractory warm ... See more keywords
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real‐world multicentre UK retrospective analysis
Sign Up to like & getrecommendations! Published in 2023 at "British Journal of Haematology"
DOI: 10.1111/bjh.18703
Abstract: Daratumumab, bortezomib and dexamethasone (DVd) is approved for patients with relapsed multiple myeloma following the CASTOR phase 3 clinical trial. This retrospective multicentre analysis assesses the overall response rate (ORR) and progression‐free survival (PFS) in… read more here.
Keywords: bortezomib; daratumumab bortezomib; multiple myeloma; first relapse ... See more keywords
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-16-2526
Abstract: Purpose: Histone deacetylase (HDAC) inhibition improves the efficacy of proteasome inhibition for multiple myeloma but adds substantial toxicity. Preclinical models suggest that the observed synergy is due to the role of HDAC6 in mediating resistance… read more here.
Keywords: combination; bortezomib dexamethasone; ricolinostat; multiple myeloma ... See more keywords
A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps8056
Abstract: TPS8056Background: Selinexor is an oral, selective inhibitor of nuclear export that specifically blocks exportin 1, leading to the nuclear accumulation & reactivation of tumor suppressor proteins. ... read more here.
Keywords: randomized controlled; bortezomib dexamethasone; controlled open; phase randomized ... See more keywords
Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0270854
Abstract: The combination of panobinostat, bortezomib and dexamethasone (PanBorDex) is available as a treatment option for relapsed refractory multiple myeloma (RRMM) based on the PANORAMA-1 trial which investigated this triplet in early relapse. In routine clinical… read more here.
Keywords: relapsed refractory; panobinostat; combination; treatment ... See more keywords
Phase II Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Over 75 Years Old with Alternating Bortezomib/dexamethasone and Lenalidomide/dexamethasone: the MARBLE Trial.
Sign Up to like & getrecommendations! Published in 2019 at "Acta medica Okayama"
DOI: 10.18926/amo/57722
Abstract: Elderly multiple myeloma (MM) patients, who are generally ineligible for transplantation, have high risks of death and treatment discontinuation, and require a regimen incorporating novel agents that balance safety, tolerability, and efficacy. We evaluated alternating… read more here.
Keywords: alternating bortezomib; multiple myeloma; myeloma patients; bortezomib dexamethasone ... See more keywords